Fig. 1

Expression of ATP6AP2 in PBMCs and ADSCs. PBMCs and ADSCs isolated from healthy or ND subjects. mRNA expression determined by RT-qPCR and normalized to GAPDH. Quantitative levels of ATP6AP2 mRNA in undifferentiated ADSCs (a, b) or PBMCs (c, d). Correlations of expression of ATP6AP2 between ADSCs and PBMCs in healthy (e) or ND (f) subjects. Correlations with isolated number of cells in ADSCs (g) or PBMCs (h). Distribution of population as a function of donor’s age (i). ADSCs differentiated into NLCs for 37 days as indicated in Methods and levels of mRNA (j), total (k) and soluble (l) proteins shown. Undifferentiated cells analyzed at day < 0 (a–h). Differentiated cells analyzed at D < 0/D0/D14/D30/D37 (j–l). *^§P < 0.05,**^§§P < 0.001,***^§§§P < 0.0005: *D0/14/30/37 vs D < 0, ^§ND vs healthy. AD Alzheimer disease, ADSC adipose-derived mesenchymal stem cell, ALS amyotrophic lateral sclerosis, D day, MS multiple sclerosis, ND neurodegenerative disease, NS not significant, PBMC peripheral blood mononuclear cell, PD, Parkinson disease